Natera, Inc. NTRA

Natera’s freshest supplied evidence is not a single dramatic headline, but a dense official rail: SEC EDGAR lists multiple June filings for NTRA, including an 8-K/A and 8-K dated 2026-06-16, a Form 144 dated 2026-06-16, Form 4 filings dated 2026-06-16 and 2026-06-17, and a separate 8-K dated 2026-06-05. That filing activity is the named public development in the pack, and it matters because this equity story is being told through official disclosure rather than rumour, price action or analyst colour.

The company’s product identity is clear from the issuer rail: Natera describes itself as a global leader in cfDNA testing, with supplied service references to oncology, organ health, women’s health and NateraCore. That does not prove a fresh launch or a new approval in this source pack. It does establish the operating frame: NTRA is a testing-services equity where revenue, research spend, inventory, customer concentration and cash generation have to be read against a real clinical-services business rather than a generic technology label.

The latest parsed financial facts come from the 10-Q for the period ending 2026-03-31. Revenue from contracts with customers, excluding assessed tax, was $696.6M. Net income attributable to parent was a loss of $85.1M, operating loss was $93.5M, and diluted earnings per share were negative $0.60 on 141.5M diluted weighted average shares. The same filing rail shows $2.61B of assets, $840.4M of liabilities and $1.77B of stockholders’ equity attributable to parent.

The cash and operating detail make the file more useful than a headline screen. Natera reported $40.2M of net cash provided by operating activities, $22.1M of payments to acquire property, plant and equipment, $210.7M of research and development expense, $70.7M of net inventory, and a $2.3M increase in inventories for the period ending 2026-03-31. The 10-Q evidence also says the company recognises revenue when, or as, performance obligations are satisfied, and that no individual customer exceeded 10% of total revenues for the three months ended March 31, 2026 and 2025.

The chart rail is not supplied in the evidence, so this report should not invent levels, candles, support, resistance or momentum language. The market mechanism here is source-led: official SEC filings define the current public record, the issuer site defines the service footprint, and the parsed 10-Q facts define the financial tension between revenue scale, operating loss, R&D spend and positive operating cash flow.

What changed is that the June disclosure tape is active and recent, while the deepest financial base still comes from the 10-Q for the period ending 2026-03-31. What remains unproven in this pack is any new product approval, fresh sales milestone, guidance update, dividend, buyback, analyst view or chart signal. A deeper file would need the contents behind the June 8-K, 8-K/A, Form 4 and Form 144 events, plus any later issuer or SEC disclosure that directly updates operations or financial outlook.